{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Corpus+Cancer", "query": { "condition": "Uterine Corpus Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 122, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Corpus+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T01:20:27.667Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00888173", "title": "Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Brivanib Alaninate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 45, "start_date": "2009-07-06", "completion_date": "2016-07-16", "has_results": true, "last_update_posted_date": "2017-12-06", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 35, "location_summary": "Aurora, Colorado • New Britain, Connecticut • Chicago, Illinois + 19 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ames", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00888173" }, { "nct_id": "NCT02208375", "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Endometrial Adenocarcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "High Grade Ovarian Serous Adenocarcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vistusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 159, "start_date": "2014-11-11", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02208375" }, { "nct_id": "NCT02342730", "title": "Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Complex Endometrial Hyperplasia With Atypia", "Stage IA Uterine Corpus Cancer", "Stage IB Uterine Corpus Cancer", "Stage II Uterine Corpus Cancer" ], "interventions": [ { "name": "Weight Loss Specialist", "type": "BEHAVIORAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Medical Chart Review", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 127, "start_date": "2014-12-17", "completion_date": "2015-05-18", "has_results": false, "last_update_posted_date": "2018-11-19", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02342730" }, { "nct_id": "NCT04269837", "title": "Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Malignant Female Reproductive System Neoplasm", "Stage I Cervical Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage I Vaginal Cancer AJCC v8", "Stage I Vulvar Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA Vaginal Cancer AJCC v8", "Stage IA Vulvar Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Uterine Corpus Cancer AJCC v8", "Stage IB Vaginal Cancer AJCC v8", "Stage IB Vulvar Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Uterine Corpus Cancer AJCC v8", "Stage II Vaginal Cancer AJCC v8", "Stage II Vulvar Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Vaginal Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Vaginal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8" ], "interventions": [ { "name": "Counseling", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2021-05-20", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2024-05-09", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04269837" }, { "nct_id": "NCT05691504", "title": "Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Platinum-Resistant Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pelcitoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 42, "start_date": "2023-09-14", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05691504" }, { "nct_id": "NCT01164735", "title": "Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Uterine Corpus Carcinoma", "Stage III Uterine Corpus Cancer", "Stage IV Uterine Corpus Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 169, "start_date": "2010-01", "completion_date": "2018-01", "has_results": false, "last_update_posted_date": "2024-08-14", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164735" }, { "nct_id": "NCT00006011", "title": "Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation", "Endometrial Serous Adenocarcinoma", "Stage III Uterine Corpus Cancer" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 659, "start_date": "2000-07", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-05-19", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006011" }, { "nct_id": "NCT00944944", "title": "Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer", "Uterine Cancer", "Vaginal Cancer", "Lymphedema" ], "interventions": [ { "name": "limb volume measurements and GCLQ lymphedema symptom assessment questionnaire", "type": "BEHAVIORAL" }, { "name": "GCLQ lymphedema symptom assessment questionnaire", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 58, "start_date": "2009-07", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2010-02-01", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00944944" }, { "nct_id": "NCT01247571", "title": "Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uterine Corpus Sarcoma", "Uterine Carcinosarcoma" ], "interventions": [ { "name": "Pazopanib Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2011-01", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2019-08-08", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 41, "location_summary": "Aurora, Colorado • Hartford, Connecticut • New Britain, Connecticut + 32 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247571" }, { "nct_id": "NCT00027690", "title": "Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Gefitinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 56, "start_date": "2002-06", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-06-11T01:20:27.667Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027690" } ] }